SgmlV1, PascalFrancis, Corpus, bibRecord, 000030

Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection

Identifieur interne : 000030 ( PascalFrancis/Corpus ); précédent : 000029; suivant : 000031

Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection

Auteurs : Achille Ambrosetti ; Roberta Zanotti ; Cristian Pattaro ; Lorenza Lenzi ; Marco Chilosi ; Paola Caramaschi ; Luca Arcaini ; Felice Pasini ; Domenico Biasi ; Ester Orlandi ; Mariella D'Adda ; Marco Lucioni ; Giovanni Pizzolo

Source :

British journal of haematology [ 0007-1048 ] ; 2004.

RBID : Pascal:04-0352747

Descripteurs français

Pascal (Inist)
- Lymphome MALT, Primaire, Salive, Hépatite virale C, Glande salivaire, Pronostic, Hématologie.

English descriptors

KwdEn :
- Hematology, MALT lymphoma, Primary, Prognosis, Saliva, Salivary gland, Viral hepatitis C.

Abstract

Salivary gland mucosa-associated lymphoid tissue (MALT) lymphomas (SGML) are rare, as are data concerning their behaviour. We analysed clinical features at presentation, particularly the association with Sjoegren syndrome (SS) and hepatitis C virus (HCV) infection, and outcome in 33 cases of SGML diagnosed between March 1985 and April 2003. There were five males and 28 females, with a median age of 61 years. At presentation, 12/33 (36%) had multiple salivary glands or mucosal involvement and four had bone marrow infiltration. Ann Arbor stage was IE in 15 (46%), IIE in four (12%) and IV in 14 patients (42%). Fifteen patients had a history of SS (46%), two of other autoimmune diseases, seven of HCV infection. No case had both SS and HCV. Of the 29 treated patients, 17 received surgery or local radiotherapy; 69% achieved complete remission. Histological transformation occurred in four (12%). Five patients died (three of lymphoma, two of unrelated causes). The 5 year-overall survival (OS), cause-specific survival and progression-free survival was 85 ± 8%, 94 ± 6% and 65 ± 10% respectively. Overall, the disease course was indolent, despite the advanced stage at diagnosis, and local therapy often appeared to be adequate. The only prognostic factors influencing OS were histological transformation and age. The close association of SGML with either autoimmune diseases or HCV infection in our series (73%) confirms their possible role in the pathogenesis of these lymphomas.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0007-1048`
A02	`01`			`@0 BJHEAL`
A03		`1`		`@0 Br. j. haematol.`
A05				`@2 126`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection`
A11	`01`	`1`		`@1 AMBROSETTI (Achille)`
A11	`02`	`1`		`@1 ZANOTTI (Roberta)`
A11	`03`	`1`		`@1 PATTARO (Cristian)`
A11	`04`	`1`		`@1 LENZI (Lorenza)`
A11	`05`	`1`		`@1 CHILOSI (Marco)`
A11	`06`	`1`		`@1 CARAMASCHI (Paola)`
A11	`07`	`1`		`@1 ARCAINI (Luca)`
A11	`08`	`1`		`@1 PASINI (Felice)`
A11	`09`	`1`		`@1 BIASI (Domenico)`
A11	`10`	`1`		`@1 ORLANDI (Ester)`
A11	`11`	`1`		`@1 D'ADDA (Mariella)`
A11	`12`	`1`		`@1 LUCIONI (Marco)`
A11	`13`	`1`		`@1 PIZZOLO (Giovanni)`
A14	`01`			`@1 Department of Clinical and Experimental Medicine, University of Verona @2 Verona @3 ITA @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 6 aut. @Z 8 aut. @Z 9 aut. @Z 11 aut. @Z 13 aut.`
A14	`02`			`@1 Department of Medicine and Public Health, University of Verona @2 Verona @3 ITA @Z 3 aut.`
A14	`03`			`@1 Department of Pathology, University of Verona @2 Verona @3 ITA @Z 5 aut.`
A14	`04`			`@1 Division of Hematology, University of Pavia @2 Pavia @3 ITA @Z 7 aut. @Z 10 aut.`
A14	`05`			`@1 Department of Pathology, University of Pavia @2 Pavia @3 ITA @Z 12 aut.`
A20				`@1 43-49`
A21				`@1 2004`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 7597 @5 354000110476370060`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.1/2`
A47	`01`	`1`		`@0 04-0352747`
A60				`@1 P @3 PR`
A61				`@0 A`
A64	`01`	`1`		`@0 British journal of haematology`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Salivary gland mucosa-associated lymphoid tissue (MALT) lymphomas (SGML) are rare, as are data concerning their behaviour. We analysed clinical features at presentation, particularly the association with Sjoegren syndrome (SS) and hepatitis C virus (HCV) infection, and outcome in 33 cases of SGML diagnosed between March 1985 and April 2003. There were five males and 28 females, with a median age of 61 years. At presentation, 12/33 (36%) had multiple salivary glands or mucosal involvement and four had bone marrow infiltration. Ann Arbor stage was IE in 15 (46%), IIE in four (12%) and IV in 14 patients (42%). Fifteen patients had a history of SS (46%), two of other autoimmune diseases, seven of HCV infection. No case had both SS and HCV. Of the 29 treated patients, 17 received surgery or local radiotherapy; 69% achieved complete remission. Histological transformation occurred in four (12%). Five patients died (three of lymphoma, two of unrelated causes). The 5 year-overall survival (OS), cause-specific survival and progression-free survival was 85 ± 8%, 94 ± 6% and 65 ± 10% respectively. Overall, the disease course was indolent, despite the advanced stage at diagnosis, and local therapy often appeared to be adequate. The only prognostic factors influencing OS were histological transformation and age. The close association of SGML with either autoimmune diseases or HCV infection in our series (73%) confirms their possible role in the pathogenesis of these lymphomas.
C02	`01`	`X`		`@0 002B19B`
C02	`02`	`X`		`@0 002B05C02G`
C03	`01`	`X`	`FRE`	`@0 Lymphome MALT @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 MALT lymphoma @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Linfoma MALT @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Primaire @5 02`
C03	`02`	`X`	`ENG`	`@0 Primary @5 02`
C03	`02`	`X`	`SPA`	`@0 Primario @5 02`
C03	`03`	`X`	`FRE`	`@0 Salive @5 03`
C03	`03`	`X`	`ENG`	`@0 Saliva @5 03`
C03	`03`	`X`	`SPA`	`@0 Saliva @5 03`
C03	`04`	`X`	`FRE`	`@0 Hépatite virale C @5 04`
C03	`04`	`X`	`ENG`	`@0 Viral hepatitis C @5 04`
C03	`04`	`X`	`SPA`	`@0 Hepatitis virica C @5 04`
C03	`05`	`X`	`FRE`	`@0 Glande salivaire @5 05`
C03	`05`	`X`	`ENG`	`@0 Salivary gland @5 05`
C03	`05`	`X`	`SPA`	`@0 Glándula salival @5 05`
C03	`06`	`X`	`FRE`	`@0 Pronostic @5 06`
C03	`06`	`X`	`ENG`	`@0 Prognosis @5 06`
C03	`06`	`X`	`SPA`	`@0 Pronóstico @5 06`
C03	`07`	`X`	`FRE`	`@0 Hématologie @5 08`
C03	`07`	`X`	`ENG`	`@0 Hematology @5 08`
C03	`07`	`X`	`SPA`	`@0 Hematología @5 08`
C07	`01`	`X`	`FRE`	`@0 Virose @2 NM`
C07	`01`	`X`	`ENG`	`@0 Viral disease @2 NM`
C07	`01`	`X`	`SPA`	`@0 Virosis @2 NM`
C07	`02`	`X`	`FRE`	`@0 Infection @2 NM`
C07	`02`	`X`	`ENG`	`@0 Infection @2 NM`
C07	`02`	`X`	`SPA`	`@0 Infección @2 NM`
C07	`03`	`X`	`FRE`	`@0 Hémopathie maligne @5 37`
C07	`03`	`X`	`ENG`	`@0 Malignant hemopathy @5 37`
C07	`03`	`X`	`SPA`	`@0 Hemopatía maligna @5 37`
C07	`04`	`X`	`FRE`	`@0 Lymphome non hodgkinien @5 38`
C07	`04`	`X`	`ENG`	`@0 Non Hodgkin lymphoma @5 38`
C07	`04`	`X`	`SPA`	`@0 Linfoma no Hodgkin @5 38`
C07	`05`	`X`	`FRE`	`@0 Lymphoprolifératif syndrome @5 39`
C07	`05`	`X`	`ENG`	`@0 Lymphoproliferative syndrome @5 39`
C07	`05`	`X`	`SPA`	`@0 Linfoproliferativo síndrome @5 39`
C07	`06`	`X`	`FRE`	`@0 Appareil digestif pathologie @5 40`
C07	`06`	`X`	`ENG`	`@0 Digestive diseases @5 40`
C07	`06`	`X`	`SPA`	`@0 Aparato digestivo patología @5 40`
C07	`07`	`X`	`FRE`	`@0 Foie pathologie @5 41`
C07	`07`	`X`	`ENG`	`@0 Hepatic disease @5 41`
C07	`07`	`X`	`SPA`	`@0 Hígado patología @5 41`
C07	`08`	`X`	`FRE`	`@0 Appareil digestif @5 43`
C07	`08`	`X`	`ENG`	`@0 Digestive system @5 43`
C07	`08`	`X`	`SPA`	`@0 Aparato digestivo @5 43`
N21				`@1 208`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 04-0352747 INIST
ET :	Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection
AU :	AMBROSETTI (Achille); ZANOTTI (Roberta); PATTARO (Cristian); LENZI (Lorenza); CHILOSI (Marco); CARAMASCHI (Paola); ARCAINI (Luca); PASINI (Felice); BIASI (Domenico); ORLANDI (Ester); D'ADDA (Mariella); LUCIONI (Marco); PIZZOLO (Giovanni)
AF :	Department of Clinical and Experimental Medicine, University of Verona/Verona/Italie (1 aut., 2 aut., 4 aut., 6 aut., 8 aut., 9 aut., 11 aut., 13 aut.); Department of Medicine and Public Health, University of Verona/Verona/Italie (3 aut.); Department of Pathology, University of Verona/Verona/Italie (5 aut.); Division of Hematology, University of Pavia/Pavia/Italie (7 aut., 10 aut.); Department of Pathology, University of Pavia/Pavia/Italie (12 aut.)
DT :	Publication en série; Papier de recherche; Niveau analytique
SO :	British journal of haematology; ISSN 0007-1048; Coden BJHEAL; Royaume-Uni; Da. 2004; Vol. 126; No. 1; Pp. 43-49; Bibl. 1 p.1/2
LA :	Anglais
EA :	Salivary gland mucosa-associated lymphoid tissue (MALT) lymphomas (SGML) are rare, as are data concerning their behaviour. We analysed clinical features at presentation, particularly the association with Sjoegren syndrome (SS) and hepatitis C virus (HCV) infection, and outcome in 33 cases of SGML diagnosed between March 1985 and April 2003. There were five males and 28 females, with a median age of 61 years. At presentation, 12/33 (36%) had multiple salivary glands or mucosal involvement and four had bone marrow infiltration. Ann Arbor stage was IE in 15 (46%), IIE in four (12%) and IV in 14 patients (42%). Fifteen patients had a history of SS (46%), two of other autoimmune diseases, seven of HCV infection. No case had both SS and HCV. Of the 29 treated patients, 17 received surgery or local radiotherapy; 69% achieved complete remission. Histological transformation occurred in four (12%). Five patients died (three of lymphoma, two of unrelated causes). The 5 year-overall survival (OS), cause-specific survival and progression-free survival was 85 ± 8%, 94 ± 6% and 65 ± 10% respectively. Overall, the disease course was indolent, despite the advanced stage at diagnosis, and local therapy often appeared to be adequate. The only prognostic factors influencing OS were histological transformation and age. The close association of SGML with either autoimmune diseases or HCV infection in our series (73%) confirms their possible role in the pathogenesis of these lymphomas.
CC :	002B19B; 002B05C02G
FD :	Lymphome MALT; Primaire; Salive; Hépatite virale C; Glande salivaire; Pronostic; Hématologie
FG :	Virose; Infection; Hémopathie maligne; Lymphome non hodgkinien; Lymphoprolifératif syndrome; Appareil digestif pathologie; Foie pathologie; Appareil digestif
ED :	MALT lymphoma; Primary; Saliva; Viral hepatitis C; Salivary gland; Prognosis; Hematology
EG :	Viral disease; Infection; Malignant hemopathy; Non Hodgkin lymphoma; Lymphoproliferative syndrome; Digestive diseases; Hepatic disease; Digestive system
SD :	Linfoma MALT; Primario; Saliva; Hepatitis virica C; Glándula salival; Pronóstico; Hematología
LO :	INIST-7597.354000110476370060
ID :	04-0352747

Links to Exploration step

Pascal:04-0352747

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection</title>
<author><name sortKey="Ambrosetti, Achille" sort="Ambrosetti, Achille" uniqKey="Ambrosetti A" first="Achille" last="Ambrosetti">Achille Ambrosetti</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zanotti, Roberta" sort="Zanotti, Roberta" uniqKey="Zanotti R" first="Roberta" last="Zanotti">Roberta Zanotti</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pattaro, Cristian" sort="Pattaro, Cristian" uniqKey="Pattaro C" first="Cristian" last="Pattaro">Cristian Pattaro</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medicine and Public Health, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lenzi, Lorenza" sort="Lenzi, Lorenza" uniqKey="Lenzi L" first="Lorenza" last="Lenzi">Lorenza Lenzi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chilosi, Marco" sort="Chilosi, Marco" uniqKey="Chilosi M" first="Marco" last="Chilosi">Marco Chilosi</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Pathology, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Caramaschi, Paola" sort="Caramaschi, Paola" uniqKey="Caramaschi P" first="Paola" last="Caramaschi">Paola Caramaschi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Arcaini, Luca" sort="Arcaini, Luca" uniqKey="Arcaini L" first="Luca" last="Arcaini">Luca Arcaini</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Hematology, University of Pavia</s1>
<s2>Pavia</s2>
<s3>ITA</s3>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pasini, Felice" sort="Pasini, Felice" uniqKey="Pasini F" first="Felice" last="Pasini">Felice Pasini</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Biasi, Domenico" sort="Biasi, Domenico" uniqKey="Biasi D" first="Domenico" last="Biasi">Domenico Biasi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Orlandi, Ester" sort="Orlandi, Ester" uniqKey="Orlandi E" first="Ester" last="Orlandi">Ester Orlandi</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Hematology, University of Pavia</s1>
<s2>Pavia</s2>
<s3>ITA</s3>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="D Adda, Mariella" sort="D Adda, Mariella" uniqKey="D Adda M" first="Mariella" last="D'Adda">Mariella D'Adda</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lucioni, Marco" sort="Lucioni, Marco" uniqKey="Lucioni M" first="Marco" last="Lucioni">Marco Lucioni</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Pathology, University of Pavia</s1>
<s2>Pavia</s2>
<s3>ITA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pizzolo, Giovanni" sort="Pizzolo, Giovanni" uniqKey="Pizzolo G" first="Giovanni" last="Pizzolo">Giovanni Pizzolo</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0352747</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0352747 INIST</idno>
<idno type="RBID">Pascal:04-0352747</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000030</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection</title>
<author><name sortKey="Ambrosetti, Achille" sort="Ambrosetti, Achille" uniqKey="Ambrosetti A" first="Achille" last="Ambrosetti">Achille Ambrosetti</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zanotti, Roberta" sort="Zanotti, Roberta" uniqKey="Zanotti R" first="Roberta" last="Zanotti">Roberta Zanotti</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pattaro, Cristian" sort="Pattaro, Cristian" uniqKey="Pattaro C" first="Cristian" last="Pattaro">Cristian Pattaro</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medicine and Public Health, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lenzi, Lorenza" sort="Lenzi, Lorenza" uniqKey="Lenzi L" first="Lorenza" last="Lenzi">Lorenza Lenzi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chilosi, Marco" sort="Chilosi, Marco" uniqKey="Chilosi M" first="Marco" last="Chilosi">Marco Chilosi</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Pathology, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Caramaschi, Paola" sort="Caramaschi, Paola" uniqKey="Caramaschi P" first="Paola" last="Caramaschi">Paola Caramaschi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Arcaini, Luca" sort="Arcaini, Luca" uniqKey="Arcaini L" first="Luca" last="Arcaini">Luca Arcaini</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Hematology, University of Pavia</s1>
<s2>Pavia</s2>
<s3>ITA</s3>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pasini, Felice" sort="Pasini, Felice" uniqKey="Pasini F" first="Felice" last="Pasini">Felice Pasini</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Biasi, Domenico" sort="Biasi, Domenico" uniqKey="Biasi D" first="Domenico" last="Biasi">Domenico Biasi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Orlandi, Ester" sort="Orlandi, Ester" uniqKey="Orlandi E" first="Ester" last="Orlandi">Ester Orlandi</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Hematology, University of Pavia</s1>
<s2>Pavia</s2>
<s3>ITA</s3>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="D Adda, Mariella" sort="D Adda, Mariella" uniqKey="D Adda M" first="Mariella" last="D'Adda">Mariella D'Adda</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lucioni, Marco" sort="Lucioni, Marco" uniqKey="Lucioni M" first="Marco" last="Lucioni">Marco Lucioni</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Pathology, University of Pavia</s1>
<s2>Pavia</s2>
<s3>ITA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pizzolo, Giovanni" sort="Pizzolo, Giovanni" uniqKey="Pizzolo G" first="Giovanni" last="Pizzolo">Giovanni Pizzolo</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">British journal of haematology</title>
<title level="j" type="abbreviated">Br. j. haematol.</title>
<idno type="ISSN">0007-1048</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">British journal of haematology</title>
<title level="j" type="abbreviated">Br. j. haematol.</title>
<idno type="ISSN">0007-1048</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Hematology</term>
<term>MALT lymphoma</term>
<term>Primary</term>
<term>Prognosis</term>
<term>Saliva</term>
<term>Salivary gland</term>
<term>Viral hepatitis C</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lymphome MALT</term>
<term>Primaire</term>
<term>Salive</term>
<term>Hépatite virale C</term>
<term>Glande salivaire</term>
<term>Pronostic</term>
<term>Hématologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Salivary gland mucosa-associated lymphoid tissue (MALT) lymphomas (SGML) are rare, as are data concerning their behaviour. We analysed clinical features at presentation, particularly the association with Sjoegren syndrome (SS) and hepatitis C virus (HCV) infection, and outcome in 33 cases of SGML diagnosed between March 1985 and April 2003. There were five males and 28 females, with a median age of 61 years. At presentation, 12/33 (36%) had multiple salivary glands or mucosal involvement and four had bone marrow infiltration. Ann Arbor stage was IE in 15 (46%), IIE in four (12%) and IV in 14 patients (42%). Fifteen patients had a history of SS (46%), two of other autoimmune diseases, seven of HCV infection. No case had both SS and HCV. Of the 29 treated patients, 17 received surgery or local radiotherapy; 69% achieved complete remission. Histological transformation occurred in four (12%). Five patients died (three of lymphoma, two of unrelated causes). The 5 year-overall survival (OS), cause-specific survival and progression-free survival was 85 ± 8%, 94 ± 6% and 65 ± 10% respectively. Overall, the disease course was indolent, despite the advanced stage at diagnosis, and local therapy often appeared to be adequate. The only prognostic factors influencing OS were histological transformation and age. The close association of SGML with either autoimmune diseases or HCV infection in our series (73%) confirms their possible role in the pathogenesis of these lymphomas.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0007-1048</s0>
</fA01>
<fA02 i1="01"><s0>BJHEAL</s0>
</fA02>
<fA03 i2="1"><s0>Br. j. haematol.</s0>
</fA03>
<fA05><s2>126</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>AMBROSETTI (Achille)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ZANOTTI (Roberta)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PATTARO (Cristian)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LENZI (Lorenza)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>CHILOSI (Marco)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CARAMASCHI (Paola)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ARCAINI (Luca)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>PASINI (Felice)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>BIASI (Domenico)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>ORLANDI (Ester)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>D'ADDA (Mariella)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>LUCIONI (Marco)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>PIZZOLO (Giovanni)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Clinical and Experimental Medicine, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Medicine and Public Health, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Pathology, University of Verona</s1>
<s2>Verona</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Division of Hematology, University of Pavia</s1>
<s2>Pavia</s2>
<s3>ITA</s3>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Pathology, University of Pavia</s1>
<s2>Pavia</s2>
<s3>ITA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA20><s1>43-49</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>7597</s2>
<s5>354000110476370060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.1/2</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0352747</s0>
</fA47>
<fA60><s1>P</s1>
<s3>PR</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>British journal of haematology</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Salivary gland mucosa-associated lymphoid tissue (MALT) lymphomas (SGML) are rare, as are data concerning their behaviour. We analysed clinical features at presentation, particularly the association with Sjoegren syndrome (SS) and hepatitis C virus (HCV) infection, and outcome in 33 cases of SGML diagnosed between March 1985 and April 2003. There were five males and 28 females, with a median age of 61 years. At presentation, 12/33 (36%) had multiple salivary glands or mucosal involvement and four had bone marrow infiltration. Ann Arbor stage was IE in 15 (46%), IIE in four (12%) and IV in 14 patients (42%). Fifteen patients had a history of SS (46%), two of other autoimmune diseases, seven of HCV infection. No case had both SS and HCV. Of the 29 treated patients, 17 received surgery or local radiotherapy; 69% achieved complete remission. Histological transformation occurred in four (12%). Five patients died (three of lymphoma, two of unrelated causes). The 5 year-overall survival (OS), cause-specific survival and progression-free survival was 85 ± 8%, 94 ± 6% and 65 ± 10% respectively. Overall, the disease course was indolent, despite the advanced stage at diagnosis, and local therapy often appeared to be adequate. The only prognostic factors influencing OS were histological transformation and age. The close association of SGML with either autoimmune diseases or HCV infection in our series (73%) confirms their possible role in the pathogenesis of these lymphomas.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B19B</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lymphome MALT</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>MALT lymphoma</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Linfoma MALT</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Primaire</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Primary</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Primario</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Salive</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Saliva</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Saliva</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Hépatite virale C</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Viral hepatitis C</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hepatitis virica C</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Glande salivaire</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Salivary gland</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Glándula salival</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Hématologie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Hematology</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hematología</s0>
<s5>08</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Hémopathie maligne</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Malignant hemopathy</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Hemopatía maligna</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Lymphome non hodgkinien</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Non Hodgkin lymphoma</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Linfoma no Hodgkin</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Lymphoprolifératif syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Lymphoproliferative syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Linfoproliferativo síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Appareil digestif pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Digestive diseases</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Aparato digestivo patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Foie pathologie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Hepatic disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Hígado patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Appareil digestif</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Digestive system</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Aparato digestivo</s0>
<s5>43</s5>
</fC07>
<fN21><s1>208</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 04-0352747 INIST</NO>
<ET>Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection</ET>
<AU>AMBROSETTI (Achille); ZANOTTI (Roberta); PATTARO (Cristian); LENZI (Lorenza); CHILOSI (Marco); CARAMASCHI (Paola); ARCAINI (Luca); PASINI (Felice); BIASI (Domenico); ORLANDI (Ester); D'ADDA (Mariella); LUCIONI (Marco); PIZZOLO (Giovanni)</AU>
<AF>Department of Clinical and Experimental Medicine, University of Verona/Verona/Italie (1 aut., 2 aut., 4 aut., 6 aut., 8 aut., 9 aut., 11 aut., 13 aut.); Department of Medicine and Public Health, University of Verona/Verona/Italie (3 aut.); Department of Pathology, University of Verona/Verona/Italie (5 aut.); Division of Hematology, University of Pavia/Pavia/Italie (7 aut., 10 aut.); Department of Pathology, University of Pavia/Pavia/Italie (12 aut.)</AF>
<DT>Publication en série; Papier de recherche; Niveau analytique</DT>
<SO>British journal of haematology; ISSN 0007-1048; Coden BJHEAL; Royaume-Uni; Da. 2004; Vol. 126; No. 1; Pp. 43-49; Bibl. 1 p.1/2</SO>
<LA>Anglais</LA>
<EA>Salivary gland mucosa-associated lymphoid tissue (MALT) lymphomas (SGML) are rare, as are data concerning their behaviour. We analysed clinical features at presentation, particularly the association with Sjoegren syndrome (SS) and hepatitis C virus (HCV) infection, and outcome in 33 cases of SGML diagnosed between March 1985 and April 2003. There were five males and 28 females, with a median age of 61 years. At presentation, 12/33 (36%) had multiple salivary glands or mucosal involvement and four had bone marrow infiltration. Ann Arbor stage was IE in 15 (46%), IIE in four (12%) and IV in 14 patients (42%). Fifteen patients had a history of SS (46%), two of other autoimmune diseases, seven of HCV infection. No case had both SS and HCV. Of the 29 treated patients, 17 received surgery or local radiotherapy; 69% achieved complete remission. Histological transformation occurred in four (12%). Five patients died (three of lymphoma, two of unrelated causes). The 5 year-overall survival (OS), cause-specific survival and progression-free survival was 85 ± 8%, 94 ± 6% and 65 ± 10% respectively. Overall, the disease course was indolent, despite the advanced stage at diagnosis, and local therapy often appeared to be adequate. The only prognostic factors influencing OS were histological transformation and age. The close association of SGML with either autoimmune diseases or HCV infection in our series (73%) confirms their possible role in the pathogenesis of these lymphomas.</EA>
<CC>002B19B; 002B05C02G</CC>
<FD>Lymphome MALT; Primaire; Salive; Hépatite virale C; Glande salivaire; Pronostic; Hématologie</FD>
<FG>Virose; Infection; Hémopathie maligne; Lymphome non hodgkinien; Lymphoprolifératif syndrome; Appareil digestif pathologie; Foie pathologie; Appareil digestif</FG>
<ED>MALT lymphoma; Primary; Saliva; Viral hepatitis C; Salivary gland; Prognosis; Hematology</ED>
<EG>Viral disease; Infection; Malignant hemopathy; Non Hodgkin lymphoma; Lymphoproliferative syndrome; Digestive diseases; Hepatic disease; Digestive system</EG>
<SD>Linfoma MALT; Primario; Saliva; Hepatitis virica C; Glándula salival; Pronóstico; Hematología</SD>
<LO>INIST-7597.354000110476370060</LO>
<ID>04-0352747</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Informatique/explor/SgmlV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000030 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000030 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Informatique
   |area=    SgmlV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:04-0352747
   |texte=   Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection
}}

This area was generated with Dilib version V0.6.33.
Data generation: Mon Jul 1 14:26:08 2019. Site generation: Wed Apr 28 21:40:44 2021

	Serveur d'exploration sur SGML
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur SGML

Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection

Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri